Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria.
BACKGROUND
Aldosterone has emerged as a deleterious hormone in the heart, with mineralocorticoid receptor (MR) blockade reducing mortality in patients with severe heart failure. There is also experimental evidence that aldosterone contributes to the development of nephrosclerosis and renal fibrosis in rodent models, but little is known of its role in clinical renal disease.


RESULTS
We quantified MR, serum- and glucocorticoid-regulated kinase 1 (sgk1), and mRNA expression of inflammatory mediators such as macrophage chemoattractant protein-1 (MCP-1), transforming growth factor-beta1, and interleukin-6 in 95 human kidney biopsies in patients with renal failure and mild to marked proteinuria of diverse etiologic origins. We measured renal function, serum aldosterone, urinary MCP-1 protein excretion, and the amount of chronic renal damage. Macrophage invasion was quantified by CD68 and vascularization by CD34 immunostaining. Serum aldosterone correlated negatively with creatinine clearance (P<0.01) and positively with renal scarring (P<0.05) but did not correlate with MR mRNA expression or proteinuria. Patients with heavy albuminuria (>2 g/24 h; n=15) had the most renal scarring and the lowest endothelial CD34 staining. This group showed a significant 5-fold increase in MR, a 2.5-fold increase in sgk1 expression and a significant increase in inflammatory mediators (7-fold increase in MCP-1, 3-fold increase in transforming growth factor-beta1, and 2-fold increase in interleukin-6 mRNA). Urinary MCP-1 protein excretion and renal macrophage invasion were significantly increased in patients with heavy albuminuria.


CONCLUSIONS
These studies support animal data linking aldosterone/MR activation to renal inflammation and proteinuria. Further studies are urgently required to assess the potential beneficial effects of MR antagonism in patients with renal disease.
Quinkler
Marcus
M
Division of Medical Sciences, University of Birmingham, Birmingham B15 2TT, UK.
Zehnder
Daniel
D
Eardley
Kevin S
KS
Lepenies
Julia
J
Howie
Alexander J
AJ
Hughes
Susan V
SV
Cockwell
Paul
P
Hewison
Martin
M
Stewart
Paul M
PM
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000450:Aldosterone / Q000097:blood*; D001706:Biopsy; D001794:Blood Pressure; D018932:Chemokine CCL2 / Q000235:genetics; D005260:Female; D050533:Glomerular Basement Membrane / Q000473:pathology; D006801:Humans; D017874:Immediate-Early Proteins / Q000235:genetics; D015850:Interleukin-6 / Q000235:genetics; D007511:Ischemia / Q000276:immunology / Q000473:pathology / Q000503:physiopathology; D007668:Kidney / Q000473:pathology* / Q000502:physiology*; D007677:Kidney Function Tests; D008297:Male; D008875:Middle Aged; D017346:Protein Serine-Threonine Kinases / Q000235:genetics; D011507:Proteinuria / Q000276:immunology / Q000473:pathology* / Q000503:physiopathology*; D012333:RNA, Messenger / Q000032:analysis; D018161:Receptors, Mineralocorticoid / Q000235:genetics*; D016212:Transforming Growth Factor beta / Q000235:genetics; D053773:Transforming Growth Factor beta1; D000099184:Serum-Glucocorticoid Regulated Kinases
D000450:Aldosterone; D018932:Chemokine CCL2; D017874:Immediate-Early Proteins; D015850:Interleukin-6; D017346:Protein Serine-Threonine Kinases; D012333:RNA, Messenger; D018161:Receptors, Mineralocorticoid; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; D000099184:Serum-Glucocorticoid Regulated Kinases; C111835:CCL2 protein, human; C508960:TGFB1 protein, human